仁和药业：控股股东仁和集团拟减持不超过300万股

Group 1 - The core point of the article is that Renhe Pharmaceutical announced a share reduction plan by its controlling shareholder, Renhe Group, intending to reduce up to 3 million shares, which is 0.2143% of the total share capital [1] - The share reduction will take place within three months after a 15 trading day period from the announcement date, using centralized bidding or block trading methods [1] - Any corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period will lead to an adjustment in the number of shares to be reduced, but the percentage of total share capital will remain unchanged [1] Group 2 - For the first half of 2025, Renhe Pharmaceutical's revenue composition shows that 99.25% comes from the pharmaceutical industry, while other businesses account for 0.75% [1] - As of the report date, Renhe Pharmaceutical has a market capitalization of 8.9 billion yuan [1]